Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 460

1.

Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease.

Stock CJW, De Lauretis A, Visca D, Daccord C, Kokosi M, Kouranos V, Margaritopoulos G, George PM, Molyneaux PL, Nihtyanova S, Chua F, Maher TM, Ong V, Abraham DJ, Denton CP, Wells AU, Wain LV, Renzoni EA.

Clin Rheumatol. 2020 Jan 8. doi: 10.1007/s10067-019-04922-6. [Epub ahead of print]

PMID:
31916109
2.

Transbronchial Cryobiopsy for the Diagnosis of Interstitial Lung Diseases: CHEST Guideline and Expert Panel Report.

Maldonado F, Danoff SK, Wells AU, Colby TV, Ryu JH, Liberman M, Wahidi MM, Frazer L, Hetzel J, Rickman O, Herth FJF, Poletti V, Yarmus L.

Chest. 2019 Nov 27. pii: S0012-3692(19)34281-3. doi: 10.1016/j.chest.2019.10.048. [Epub ahead of print]

PMID:
31783014
3.

Cost-effectiveness of Ambulatory Oxygen in improving quality of life in fibrotic lung disease: Preliminary evidence from the AmbOx Trial.

Whitty JA, Rankin J, Visca D, Tsipouri V, Mori L, Spencer L, Adamali H, Maher TM, Hopkinson NS, Birring SS, Farquhar M, Wells AU, Sestini P, Renzoni EA.

Eur Respir J. 2019 Nov 7. pii: 1901157. doi: 10.1183/13993003.01157-2019. [Epub ahead of print] No abstract available.

PMID:
31699838
4.

Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease.

Alfieri V, Crisafulli E, Visca D, Chong WH, Stock C, Mori L, de Lauretis A, Tsipouri V, Chua F, Kouranos V, Kokosi M, Hogben C, Molyneaux PL, George PM, Maher TM, Chetta AA, Sestini P, Wells AU, Renzoni EA.

Eur Respir J. 2019 Nov 14. pii: 1901681. doi: 10.1183/13993003.01681-2019. [Epub ahead of print] No abstract available.

PMID:
31699833
5.

Diffuse alveolar haemorrhage associated with subsequent development of ANCA positivity and emphysema in three young adults.

Stainer A, Rice A, Devaraj A, Barnett JL, Donovan J, Kokosi M, Nicholson AG, Cairns T, Wells AU, Renzoni EA.

BMC Pulm Med. 2019 Oct 24;19(1):185. doi: 10.1186/s12890-019-0947-y.

6.

Risk factors for disease progression in idiopathic pulmonary fibrosis.

Raghu G, Ley B, Brown KK, Cottin V, Gibson KF, Kaner RJ, Lederer DJ, Noble PW, Song JW, Wells AU, Whelan TP, Lynch DA, Humphries SM, Moreau E, Goodman K, Patterson SD, Smith V, Gong Q, Sundy JS, O'Riordan TG, Martinez FJ.

Thorax. 2020 Jan;75(1):78-80. doi: 10.1136/thoraxjnl-2019-213620. Epub 2019 Oct 14.

PMID:
31611341
7.

Pamrevlumab in idiopathic pulmonary fibrosis.

Wells AU.

Lancet Respir Med. 2020 Jan;8(1):2-3. doi: 10.1016/S2213-2600(19)30339-X. Epub 2019 Sep 28. No abstract available.

PMID:
31575507
8.

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators.

N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29.

PMID:
31566307
9.

Pleuroparenchymal Fibroelastosis. A Review of Clinical, Radiological, and Pathological Characteristics.

Chua F, Desai SR, Nicholson AG, Devaraj A, Renzoni E, Rice A, Wells AU.

Ann Am Thorac Soc. 2019 Nov;16(11):1351-1359. doi: 10.1513/AnnalsATS.201902-181CME.

10.

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.

Nathan SD, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez FJ, Corte TJ, Keogh AM, Leuchte H, Mogulkoc N, Ulrich S, Wuyts WA, Yao Z, Boateng F, Wells AU.

Lancet Respir Med. 2019 Sep;7(9):780-790. doi: 10.1016/S2213-2600(19)30250-4. Epub 2019 Aug 12.

PMID:
31416769
11.

Evaluation of inter-observer variation for computed tomography identification of childhood interstitial lung disease.

Jacob J, Owens CM, Brody AS, Semple T, Watson TA, Calder A, Garcia-Peña P, Toma P, Devaraj A, Walton H, Moreno-Galdó A, Aurora P, Rice A, Vece TJ, Cunningham S, Altmann A, Wells AU, Nicholson AG, Bush A.

ERJ Open Res. 2019 Jul 29;5(3). pii: 00100-2019. doi: 10.1183/23120541.00100-2019. eCollection 2019 Jul.

12.

Treatment of cardiac sarcoidosis.

Kouranos V, Wells AU, Sharma R.

Curr Opin Pulm Med. 2019 Sep;25(5):519-525. doi: 10.1097/MCP.0000000000000611.

PMID:
31365386
13.

Treatment of cardiac sarcoidosis.

Kouranos V, Wells AU, Sharma R.

Curr Opin Pulm Med. 2019 Jul 24. doi: 10.1097/MCP.0000000000000611. [Epub ahead of print]

PMID:
31343492
14.

Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis.

Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown KK, Corte TJ, Cottin V, Crestani B, Flaherty KR, Glaspole IN, Grutters J, Inoue Y, Kondoh Y, Kreuter M, Johannson KA, Ley B, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts WA, Wells AU.

Am J Respir Crit Care Med. 2019 Nov 1;200(9):1146-1153. doi: 10.1164/rccm.201903-0493OC.

15.

Diagnosing complications and co-morbidities of fibrotic interstitial lung disease.

Margaritopoulos GA, Kokosi MA, Wells AU.

Expert Rev Respir Med. 2019 Jul;13(7):645-658. doi: 10.1080/17476348.2019.1632196. Epub 2019 Jul 5.

PMID:
31215263
16.

Novel exploratory data in interstitial lung disease.

Wells AU.

Respirology. 2019 Aug;24(8):718-719. doi: 10.1111/resp.13621. Epub 2019 Jun 18. No abstract available.

17.

Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis.

Jacob J, Bartholmai BJ, van Moorsel CHM, Rajagopalan S, Devaraj A, van Es HW, Moua T, van Beek FT, Clay R, Veltkamp M, Kokosi M, de Lauretis A, Judge EP, Jacob TM, Peikert T, Karwoski R, Maldonado F, Renzoni E, Maher TM, Altmann A, Wells AU.

Eur Respir J. 2019 Sep 30;54(3). pii: 1802341. doi: 10.1183/13993003.02341-2018. Print 2019 Sep. No abstract available.

18.

Variable utility of mosaic attenuation to distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis.

Barnett J, Molyneaux PL, Rawal B, Abdullah R, Hare SS, Vancheeswaran R, Desai SR, Maher TM, Wells AU, Devaraj A.

Eur Respir J. 2019 Jul 25;54(1). pii: 1900531. doi: 10.1183/13993003.00531-2019. Print 2019 Jul.

PMID:
31164428
19.

Bromodomain and Extraterminal (BET) Protein Inhibition Restores Redox Balance and Inhibits Myofibroblast Activation.

Stock CJW, Michaeloudes C, Leoni P, Durham AL, Mumby S, Wells AU, Chung KF, Adcock IM, Renzoni EA, Lindahl GE.

Biomed Res Int. 2019 Apr 18;2019:1484736. doi: 10.1155/2019/1484736. eCollection 2019.

20.

Clinical trial design for acute exacerbations in idiopathic pulmonary fibrosis: A thorny path.

Renzoni EA, Wells AU.

Respirology. 2019 Jul;24(7):620-621. doi: 10.1111/resp.13584. Epub 2019 May 15. No abstract available.

21.

Visual and Automated CT Measurements of Lung Volume Loss in Idiopathic Pulmonary Fibrosis.

Robbie H, Wells AU, Jacob J, Walsh SLF, Nair A, Srikanthan A, Tazoniero P, Devaraj A.

AJR Am J Roentgenol. 2019 Aug;213(2):318-324. doi: 10.2214/AJR.18.20884. Epub 2019 May 7.

PMID:
31063425
22.

The King's Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference.

Sinha A, Patel AS, Siegert RJ, Bajwah S, Maher TM, Renzoni EA, Wells AU, Higginson IJ, Birring SS.

BMJ Open Respir Res. 2019 Feb 18;6(1):e000363. doi: 10.1136/bmjresp-2018-000363. eCollection 2019.

23.

In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia is associated with disease progression and mortality.

Mackintosh JA, Desai SR, Adamali H, Patel K, Chua F, Devaraj A, Kouranos V, Kokosi M, Margaritopoulos G, Renzoni EA, Wells AU, Molyneaux PL, Kumar S, Maher TM, George PM.

Eur Respir J. 2019 May 23;53(5). pii: 1802412. doi: 10.1183/13993003.02412-2018. Print 2019 May. No abstract available.

PMID:
30923184
24.

Pulmonary fibrosis: "idiopathic" is not "cryptogenic".

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group; IPF Consensus Working Group:.

Eur Respir J. 2019 Mar 18;53(3). pii: 1900400. doi: 10.1183/13993003.00400-2019. Print 2019 Mar. No abstract available.

PMID:
30886028
25.

Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis.

Witt S, Krauss E, Barbero MAN, Müller V, Bonniaud P, Vancheri C, Wells AU, Vasakova M, Pesci A, Klepetko W, Seeger W, Crestani B, Leidl R, Holle R, Schwarzkopf L, Guenther A.

Respir Res. 2019 Mar 1;20(1):47. doi: 10.1186/s12931-019-1010-5.

26.

Quantitative CT-derived vessel metrics in idiopathic pulmonary fibrosis: A structure-function study.

Jacob J, Pienn M, Payer C, Urschler M, Kokosi M, Devaraj A, Wells AU, Olschewski H.

Respirology. 2019 May;24(5):445-452. doi: 10.1111/resp.13485. Epub 2019 Feb 20.

27.

Idiopathic pulmonary fibrosis: prognostic impact of histologic honeycombing in transbronchial lung cryobiopsy.

Ravaglia C, Bosi M, Wells AU, Gurioli C, Gurioli C, Dubini A, Piciucchi S, Puglisi S, Mascetti S, Arcadu A, Tomassetti S, Poletti V.

Multidiscip Respir Med. 2019 Feb 8;14:3. doi: 10.1186/s40248-019-0170-y. eCollection 2019.

28.

Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name?

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group; IPF Consensus Working Group:.

Eur Respir J. 2019 Feb 14;53(2). pii: 1801939. doi: 10.1183/13993003.01939-2018. Print 2019 Feb. No abstract available.

PMID:
30765483
29.

Lung CT Densitometry in Idiopathic Pulmonary Fibrosis for the Prediction of Natural Course, Severity, and Mortality.

Loeh B, Brylski LT, von der Beck D, Seeger W, Krauss E, Bonniaud P, Crestani B, Vancheri C, Wells AU, Markart P, Breithecker A, Guenther A.

Chest. 2019 May;155(5):972-981. doi: 10.1016/j.chest.2019.01.019. Epub 2019 Feb 8.

PMID:
30742809
30.

Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis.

Brown KK, Flaherty KR, Cottin V, Raghu G, Inoue Y, Azuma A, Huggins JT, Richeldi L, Stowasser S, Stansen W, Schlenker-Herceg R, Maher TM, Wells AU.

Respir Med. 2019 Jan;146:42-48. doi: 10.1016/j.rmed.2018.11.012. Epub 2018 Nov 19.

31.

Diagnostic yield and risk/benefit analysis of trans-bronchial lung cryobiopsy in diffuse parenchymal lung diseases: a large cohort of 699 patients.

Ravaglia C, Wells AU, Tomassetti S, Gurioli C, Gurioli C, Dubini A, Cavazza A, Colby TV, Piciucchi S, Puglisi S, Bosi M, Poletti V.

BMC Pulm Med. 2019 Jan 16;19(1):16. doi: 10.1186/s12890-019-0780-3.

32.

Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases.

Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, Skowasch D, Park JS, Poonyagariyagorn HK, Wuyts W, Wells AU.

Eur Respir Rev. 2018 Dec 21;27(150). pii: 180076. doi: 10.1183/16000617.0076-2018. Print 2018 Dec 31. Review.

33.

Predicting outcomes in rheumatoid arthritis related interstitial lung disease.

Jacob J, Hirani N, van Moorsel CHM, Rajagopalan S, Murchison JT, van Es HW, Bartholmai BJ, van Beek FT, Struik MHL, Stewart GA, Kokosi M, Egashira R, Brun AL, Cross G, Barnett J, Devaraj A, Margaritopoulos G, Karwoski R, Renzoni E, Maher TM, Wells AU.

Eur Respir J. 2019 Jan 3;53(1). pii: 1800869. doi: 10.1183/13993003.00869-2018. Print 2019 Jan.

34.

Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis.

Nathan SD, Costabel U, Glaspole I, Glassberg MK, Lancaster LH, Lederer DJ, Pereira CA, Trzaskoma B, Morgenthien EA, Limb SL, Wells AU.

Chest. 2019 Apr;155(4):712-719. doi: 10.1016/j.chest.2018.11.008. Epub 2018 Nov 22.

35.

Pirfenidone improves survival in IPF: results from a real-life study.

Margaritopoulos GA, Trachalaki A, Wells AU, Vasarmidi E, Bibaki E, Papastratigakis G, Detorakis S, Tzanakis N, Antoniou KM.

BMC Pulm Med. 2018 Nov 23;18(1):177. doi: 10.1186/s12890-018-0736-z.

36.

The potential impact of azithromycin in idiopathic pulmonary fibrosis.

Macaluso C, Maritano Furcada J, Alzaher O, Chaube R, Chua F, Wells AU, Maher TM, George PM, Renzoni EA, Molyneaux PL.

Eur Respir J. 2019 Feb 14;53(2). pii: 1800628. doi: 10.1183/13993003.00628-2018. Print 2019 Feb. No abstract available.

PMID:
30442715
37.

Variable radiological lung nodule evaluation leads to divergent management recommendations.

Nair A, Bartlett EC, Walsh SLF, Wells AU, Navani N, Hardavella G, Bhalla S, Calandriello L, Devaraj A, Goo JM, Klein JS, MacMahon H, Schaefer-Prokop CM, Seo JB, Sverzellati N, Desai SR; Lung Nodule Evaluation Group; Lung Nodule Evaluation Group.

Eur Respir J. 2018 Dec 20;52(6). pii: 1801359. doi: 10.1183/13993003.01359-2018. Print 2018 Dec.

PMID:
30409817
38.

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice.

Fletcher SV, Jones MG, Renzoni EA, Parfrey H, Hoyles RK, Spinks K, Kokosi M, Kwok A, Warburton C, Titmuss V, Thillai M, Simler N, Maher TM, Brereton CJ, Chua F, Wells AU, Richeldi L, Spencer LG.

ERJ Open Res. 2018 Oct 19;4(4). pii: 00049-2018. doi: 10.1183/23120541.00049-2018. eCollection 2018 Oct.

39.

Sarcoidosis: A benign disease or a culture of neglect?

Wells AU.

Respir Med. 2018 Nov;144S:S1-S2. doi: 10.1016/j.rmed.2018.10.004. Epub 2018 Oct 6. No abstract available.

PMID:
30336997
40.

Author Correction: Major lung complications of systemic sclerosis.

Denton CP, Wells AU, Coghlan JG.

Nat Rev Rheumatol. 2018 Nov;14(11):682. doi: 10.1038/s41584-018-0108-3.

PMID:
30317249
41.

Efficacy data in treatment extension studies of idiopathic pulmonary fibrosis: interpret with caution.

Wells AU.

Lancet Respir Med. 2019 Jan;7(1):7-8. doi: 10.1016/S2213-2600(18)30385-0. Epub 2018 Sep 14. No abstract available.

PMID:
30224324
42.

IPF diagnosis: flexibility is a virtue.

Wells AU.

Lancet Respir Med. 2018 Oct;6(10):735-737. doi: 10.1016/S2213-2600(18)30374-6. Epub 2018 Sep 14. No abstract available. Erratum in: Lancet Respir Med. 2018 Oct;6(10):e53.

PMID:
30224321
43.

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.

Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ; INSTAGE Investigators.

N Engl J Med. 2018 Nov 1;379(18):1722-1731. doi: 10.1056/NEJMoa1811737. Epub 2018 Sep 15.

PMID:
30220235
44.

Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial.

Visca D, Mori L, Tsipouri V, Fleming S, Firouzi A, Bonini M, Pavitt MJ, Alfieri V, Canu S, Bonifazi M, Boccabella C, De Lauretis A, Stock CJW, Saunders P, Montgomery A, Hogben C, Stockford A, Pittet M, Brown J, Chua F, George PM, Molyneaux PL, Margaritopoulos GA, Kokosi M, Kouranos V, Russell AM, Birring SS, Chetta A, Maher TM, Cullinan P, Hopkinson NS, Banya W, Whitty JA, Adamali H, Spencer LG, Farquhar M, Sestini P, Wells AU, Renzoni EA.

Lancet Respir Med. 2018 Oct;6(10):759-770. doi: 10.1016/S2213-2600(18)30289-3. Epub 2018 Aug 28.

45.

The Clinical Significance of Body Weight Loss in Idiopathic Pulmonary Fibrosis Patients.

Nakatsuka Y, Handa T, Kokosi M, Tanizawa K, Puglisi S, Jacob J, Sokai A, Ikezoe K, Kanatani KT, Kubo T, Tomioka H, Taguchi Y, Nagai S, Chin K, Mishima M, Wells AU, Hirai T.

Respiration. 2018;96(4):338-347. doi: 10.1159/000490355. Epub 2018 Aug 21.

46.

Major lung complications of systemic sclerosis.

Denton CP, Wells AU, Coghlan JG.

Nat Rev Rheumatol. 2018 Sep;14(9):511-527. doi: 10.1038/s41584-018-0062-0. Review. Erratum in: Nat Rev Rheumatol. 2018 Nov;14(11):682.

PMID:
30111804
47.

Sarcoidosis: is cryobiopsy not cool enough? - Authors' reply.

Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU.

Lancet Respir Med. 2018 Sep;6(9):e45. doi: 10.1016/S2213-2600(18)30217-0. Epub 2018 Jul 11. No abstract available.

PMID:
30007850
48.

Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis.

Wu X, Kim GH, Salisbury ML, Barber D, Bartholmai BJ, Brown KK, Conoscenti CS, De Backer J, Flaherty KR, Gruden JF, Hoffman EA, Humphries SM, Jacob J, Maher TM, Raghu G, Richeldi L, Ross BD, Schlenker-Herceg R, Sverzellati N, Wells AU, Martinez FJ, Lynch DA, Goldin J, Walsh SLF.

Am J Respir Crit Care Med. 2019 Jan 1;199(1):12-21. doi: 10.1164/rccm.201803-0444PP. No abstract available.

49.

Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry.

Baughman RP, Shlobin OA, Wells AU, Alhamad EH, Culver DA, Barney J, Cordova FC, Carmona EM, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS, Kouranos V, O'Hare L, Baran JM, Cal JG, Lower EE, Engel PJ, Nathan SD.

Respir Med. 2018 Jun;139:72-78. doi: 10.1016/j.rmed.2018.04.015. Epub 2018 May 5.

PMID:
29858005
50.

What's in a name? That which we call IPF, by any other name would act the same.

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group.

Eur Respir J. 2018 May 17;51(5). pii: 1800692. doi: 10.1183/13993003.00692-2018. Print 2018 May. Review.

Supplemental Content

Loading ...
Support Center